Inclusion Criteria:

- Histopathologically documented invasive epithelial ovarian carcinoma, cancer of the
fallopian tube or the peritoneum refractory to platinum-based chemotherapy or with
partially platinum sensitive disease.

- Planned therapy with pegylated liposomal doxorubicin 50 mg/m² for recurrent
platinum-refractory ovarian cancer.

- Patients with a progression-free-interval of 6 to 12 months after platinum-based
chemotherapy are only eligible if a further course of platinum-based combination
chemotherapy is not possible as judged by the investigator(s).

- Patients must have received at least one previous platinum- and taxane-based
chemotherapy regimen.

Exclusion Criteria:

- Brain metastases or spinal cord compression, unless treated at least 4 weeks before
first dose and stable without steroid treatment for 10 days

- Any concomitant medications that may cause QTc prolongation or induce Torsades de
Pointes or induce CYP3A4 function

- Treatment with mouse-antibodies in patients with evaluable disease and CA-125
progressive disease in the last 3 months. These patients are only eligible in case of
measurable disease according to RECIST or cytological/histological proven relapse

- More than two prior lines of chemotherapy.

- Any chemotherapy or other systemic anti-cancer therapy within four weeks prior to
randomization.

- Radiation therapy within the last 4 weeks prior to randomization (with the exception
of palliative radiotherapy